Illumina, Inc. vs Rigetti Computing Inc — how do they compare? Illumina, Inc. trades at $278 (market cap $39.95B), while Rigetti Computing Inc trades at $14.05 (market cap $4.72B). The key difference: Illumina, Inc. is far larger — about 8.5× Rigetti Computing Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Rigetti Computing Inc for 35 Days on average.
| ILMN | RGTI | |
|---|---|---|
Market Cap | $39.95B | $4.72B |
Volume | 3,169,503 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $293.69 | $56.34 |
52-Week Low | $91.00 | $12.90 |
Typical Hold Time | 83 Days | 35 Days |
Enterprise Value | $41.31B | $4.33B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
RGTI trades at $14.04, down 3.77% today, with a bearish technical signal despite bullish oscillators. The company shows minimal revenue of $7.09M in 2025 with a massive net loss of -$216.21M, resulting in negative profit margins. Analyst consensus is strongly bullish with 6 buy ratings and a $21.67 price target, representing 54% upside. Recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC strategy with partners like HPE.
While analyst optimism and quantum computing potential offer significant upside, RGTI faces substantial execution risks with negative cash flow, high valuation multiples, and intense competition. The stock presents high-risk/high-reward potential for investors willing to tolerate volatility in exchange for quantum computing exposure, but requires careful monitoring of commercialization progress and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →